

RedDress **ActiGraft**

RECREATING THE NATURAL
WOUND HEALING ENVIRONMENT



INTRODUCING ACTIGRAFT

ActiGraft® is an FDA-cleared wound care solution that enables health care providers to produce—in real time—in vitro blood clots from a patient's whole blood. Once applied, the blood clot tissue serves as a protective covering and supports wound healing processes which naturally occur in the patient's body.

FEATURES & BENEFITS

COST-EFFECTIVE

Provides significant savings in nursing costs and simplifies wound treatment

EFFICIENT

Provides the wound with an optimal, natural healing environment allowing the healing process to proceed unhindered

SIMPLE

Can be easily prepared at the patient's bedside in 8 minutes and requires no capital equipment

AUTOLOGOUS

Uses the patient's own blood to support the body's own healing processes

EASE OF PAIN

Minimal handling of the wound provides a more comfortable treatment for patients




ACTIGRAFT INTENDED USE


ActiGraft is topically applied for the management of exuding cutaneous wounds, such as leg ulcers, pressure ulcers, diabetic ulcers, and mechanically or surgically-debrided wounds.

HOW ACTIGRAFT WORKS


RedDress's ActiGraft® technology is revolutionizing the way we treat chronic wounds by managing each stage of the wound healing process. ActiGraft uses a patient's own blood to create a whole blood clot tissue. This blood clot tissue is then applied to the wound, where it supports the natural healing processes of the body.




Hemostasis: The body works to stop the bleeding and start the healing process by activating a coagulation cascade. A fibrin blood clot forms that plugs severed blood vessels and fills in tissue discontinuity at the wound site.



Inflammation: During this phase, white blood cells and macrophages enter the wound to destroy bacteria and remove debris. The blood clot creates a fibrin scaffold that serves as a protective, provisional extracellular matrix (ECM) containing cytokines and growth factors that facilitate tissue repair.



Proliferation: The blood clot recruits endothelial cells and fibroblasts to synthesize a permanent ECM. The focus is filling and covering the wound.



Remodeling: The blood clot dries out and becomes a protective scab. Under the scab, tissue remodeling takes place undisturbed. The fibrin is replaced by fibronectin and hyaluronan, and the scab falls off to reveal a collagenous scar.

Case Example 1: TMA Wound

95% Wound Reduction, Total Healing in 9 Weeks with 1 ActiGraft Application

Patient Information

67 year old Female with diabetes mellitus | Failed ray amputation on TMA | Gangrene of the great toe | End-stage renal disease | Peripheral vascular disease

2 months of unsuccessful treatment with Standard of Care | Healing after 9 weeks with 1 ActiGraft Treatment



Initial observation



Week 9

Case Example 2: Latrogenic Vascular Ulcer

100% Wound Reduction, Total Healing in 5 Weeks with 4 ActiGraft Applications

Patient Information

37 year old Female with diabetes mellitus | Right lateral malleolus | 8 week old ulcer, 16cm²

2 months of unsuccessful treatment with Standard of Care | Healing after 5 weeks with 4 ActiGraft Treatments



Initial observation



Week 5

RECREATING THE NATURAL WOUND HEALING ENVIRONMENT WITH ACTIGRAFT


Evidence from clinical trials demonstrate high effectiveness in supporting the healing of hard-to-treat wounds and ulcers with the use of an autologous blood clot.

WOUND CLOSURE

- **72%** of chronic wounds in RedDress' clinical trials had completely healed¹

WOUND REDUCTION

- **62%** area reduction at 4 weeks¹



MICROSCOPIC VIEW OF ACTIGRAFT

Case Example 3: Diabetic Foot Ulcer

100% Wound Reduction, Total Healing in 11 Weeks with 4 ActiGraft Applications

Patient Information

67 year old Male, paraplegic with diabetes mellitus | Neuropathy | Anemic | HTN | HPL | OA | 89 week old ulcer, 2.60cm² x 0.3cm draining small amounts of serous drainage

21 months of unsuccessful treatment with Standard of Care | Healing after 11 weeks with 4 ActiGraft Treatments



Initial observation



Week 11

Case Example 4: Diabetic Foot Ulcer

100% Wound Reduction, Total Healing in 5 Weeks with 4 ActiGraft Applications

Patient Information

59 year old Male with diabetes mellitus | Hypertension | HL | Charcot arthropathy | 18 week old ulcer 2.5 cm² x 0.3 cm with minimal serous drainage

4 months of unsuccessful treatment with Standard of Care | Healing after 5 weeks with 4 ActiGraft Treatments



Initial observation



Week 5

ACTIGRAFT SYSTEM COMPONENTS



The ActiGraft® System provides single-use components needed for the safe and rapid preparation of Whole Blood Clot (WBC) tissue from a small sample of a patient's own peripheral blood. Each system is packed in an individual box and contains all the components needed to prepare ActiGraft.

Patient Phlebotomy System:

- Gauze pad
- ACD-A tubes (2)
- Bandage
- 18" Tourniquet
- Blood collection set with 21G needle
- Alcohol Pad

Coagulation & Accelerator System:

- 5mL Sterile ampoule of calcium gluconate
- Clotting blister containing 25mg kaolin powder

System Accessories:

- Gloves
- Drape
- Gauze
- Steri-strip
- Non adherent dressing
- Hydrophilic Foam Dressing
- Face mask with eye protection
- Tape, Ø .5" circle band-aid

RedDress® is committed to improving the health and lives of patients around the world by revolutionizing the way we treat chronic wounds. Our innovative products are advanced, biologic wound care solutions that recreate the natural wound healing processes of the body.

VISIT US AT REDDRESSMEDICAL.COM

USA

822 A1A North, Ste 310
Ponte Vedra Beach, FL 32082

Tel.: +1.800.674.9615
Fax: +1.800.561.8127
customerservice@reddressmedical.com

RedDress

¹ Donner, B, et al. "Analysis of Three Prospective, Open-Label, Clinical Trials with Autologous Blood Clot in Chronic Wounds."